Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Diagnosis of RA according to the ACR-Criteria.~* Eligible for treatment with etanercept according to Summary of Product Characteristics (SmPC), and applicable local guidelines.~* Willing and able to self-inject etanercept.~Exclusion:~* Prior experience of biologics and anti-TNF treatment for their RA including etanercept.~* Sepsis or risk of sepsis.~* Current or recent infections, including chronic or localized.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enbrel 50 mg Prefilled Syringe (Type: EXPERIMENTAL): Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
- Enbrel 50 mg Autoinjector (Type: EXPERIMENTAL): Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector

Based on this trial design, predict the completion outcome and termination type (if applicable).